The parents of every patient gave written informed consent. The University of Manitoba Health Research Ethics Table approved the study. The clinical characteristics of the individuals are summarized in Table S1 in the Supplementary Appendix, obtainable with the entire text of this content at NEJM.org. Patient 1 became ill at 1 month old with oral candidiasis and feeding difficulties. At 4 months of age, she experienced Escherichia coli septicemia, parainfluenza virus type 1 pneumonia, and persistent oral candidiasis.Amgen funded both studies. Site investigators gathered the info, and Amgen executed the data analyses. All the authors interpreted the data and, after an initial draft had been compiled by the first writer, collaborated in the preparation of the manuscript, with support from a specialist medical article writer who was a worker of Amgen. All the authors made the decision to submit the manuscript for publication and verify the veracity and completeness of data and analyses because of their respective studies, as well for the fidelity of the report to the scholarly research protocols, offered by NEJM.org. The AMAGINE-2 research was conducted at 142 sites worldwide from August 2012 through September 2014 . The AMAGINE-3 study was conducted at 142 sites worldwide from September 2012 through August 2014 .